nach oben

Erschienen in:

01.06.2015 | original article

Serum paraoxonase activity, total thiols levels, and oxidative status in patients with acute brucellosis

verfasst von: Ramazan Esen, Dr. Mehmet Aslan, Mehmet Emin Kucukoglu, Aytekin Cıkman, Umit Yakan, Mahmut Sunnetcioglu, Sahbettin Selek

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 11-12/2015

Einloggen, um Zugang zu erhalten

Summary

It is well known that paraoxonase-1 (PON1) activity may decrease during the course of infection and inflammation. The aim of this study was to investigate serum PON1 activity, oxidative status, and thiols levels in patients with acute brucellosis. In addition, we investigated the PON1 phenotype in patients with acute brucellosis. Thirty patients with acute brucellosis and 35 healthy controls were enrolled. Serum paraoxonase and arylesterase activities, thiols levels, lipid hydroperoxide levels, total antioxidant capacity (TAC), total oxidant status (TOS) and oxidative stress index (OSI) were determined. Serum basal and salt-stimulated paraoxonase–arylesterase activities, TAC levels and thiols levels were significantly lower in patients with acute brucellosis than controls (for all, p < 0.05), while LOOH levels, TOS levels, and OSI values were significantly higher (for all, p < 0.05). We concluded that oxidative stress is increased, while serum PON1 activity is decreased in patients with acute brucellosis. These results indicate that lower PON1 activity is associated with oxidant–antioxidant imbalance.

Vorheriger Artikel Effect of airborne hydrogen peroxide on spores of Clostridium difficile

Nächster Artikel Patient’s and physician’s behavior on the management of benign prostatic hyperplasia among the patients at the risk of clinical progression. A multicenter noninterventional trial in Slovakia by “Prostate and Expectations of Treatment: Epidemiology Research” (PETER) study group

Ertek M, Yazgı H, Kadanalı A, Özden K, Ta¸syaran MA. Complications of Brucella infection among adults: an 18-year retrospective evaluation. Turk J Med Sci. 2006;36:377–81.

Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med. 2005;352:2325–36.PubMedCrossRef

Colmenero JD, Reguera JM, Martos F, et al. Complications associated with brucella melitensis infection: a study of 530 Cases. Medicine (Baltimore). 1996;75:195–211.CrossRef

Gantt KR, Goldman TL, McCormick ML, et al. Oxidative response of human and murine macrophages during phagocytosis of Leishmania chagasi. J Immunol. 2001;167:893–901.PubMedCrossRef

Dieffenbach CW, Tramont EC. Innate (general or nonspecific) host defense mechanisms. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6. ed. Philadelphia: Elsevier Churchill Livingstone; 2005;34–42.

Melek IM, Erdogan S, Celik S, Aslantas O, Duman T. Evaluation of oxidative stress and inflammation in long term Brucella melitensis infection. Mol Cell Biochem. 2006;293:203–9.PubMedCrossRef

Jiang X, Baldwin CL. Macrophage control of Brucella abortus: role of reactive oxygen intermediates and nitric oxide. Cell Immunol. 1993;151:309–19.PubMedCrossRef

Serefhanoglu K, Taskin A, Turan H, Timurkaynak FE, Arslan H, Erel O. Evaluation of oxidative status in patients with brucellosis. Braz J Infect Dis. 2009;13(4):249–51.PubMedCrossRef

Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem. 1993;211:871–9.PubMedCrossRef

10.

Kosaka T, Yamaguchi M, Motomura T, Mizuno K. Investigation of the relationship between atherosclerosis and paraoxonase or homocysteine thiolactonase activity in patients with type 2 diabetes mellitus using a commercially available assay. Clin Chim Acta. 2005;359:156–62.PubMedCrossRef

11.

Ng CJ, Shih DM, Hama SY, Villa N, NavabM, Reddy ST. The paraoxonase gene family and atherosclerosis. Free Radical Biol Med. 2005;38:153–63.CrossRef

12.

Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knock out mice. Free Radical Biol Med. 2003;34:774–84.CrossRef

13.

Kotur-Stevuljevic J, Spasic S, Jelic-Ivanovic Z, et al. PON1 status is influenced by oxidative stress and inflammation in coronary heart disease patients. Clin Biochem. 2008;41:1067–73.PubMedCrossRef

14.

Kabaroglu C, Mutaf I, Boydak B, et al. Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes. Acta Cardiol. 2004;59(6):606–11.PubMedCrossRef

15.

Cabana VG, Reardon CA, Feng N, Neath S, Lukens J, Getz GS. Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. J Lipid Res. 2003;44:780–92.PubMedCrossRef

16.

Karakucuk S, Baskol G, Oner AO, Baskol M, Mirza E, Ustdal M. Serum paraoxonase activity is decreased in the active stage of Behcet’s disease. Br J Ophthalmol. 2004;88:1256–8.PubMedCentralPubMedCrossRef

17.

Demirpence O, Sevim B, Yıldırım M, Ayan Nurlu N, Mert D, Evliyaoglu O. Serum paraoxonase, TAS, TOS and ceruloplasmin in brucellosis. Int J Clin Exp Med. 2014;7(6):1592–7.PubMedCentralPubMed

18.

Apostolou F, Gazi IF, Kostoula A, et al. Persistence of an atherogenic lipid profile after treatment of acute infection with brucella. J Lipid Res. 2009;50:2532–9.PubMedCentralPubMedCrossRef

19.

Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radicalcation. Clin Biochem. 2004;37:277–85.PubMedCrossRef

20.

Sodergren E, Nourooz-Zadeh J, Berglund L, Vessby B. Re-evaluation of the ferrous oxidation in xylenol orange assay for the measurement of plasma lipid hydroperoxides. J Biochem Biophys Methods. 1998;37(3):137–46.PubMedCrossRef

21.

Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37:112–9.PubMedCrossRef

22.

Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38:1103–11.PubMedCrossRef

23.

Bolukbas C, Bolukbas FF, Horoz M, Aslan M, Celik H, Erel O. Increased oxidative stress associated with the severity of the liver disease in various forms of hepatitis B virus infection. BMC Infect Dis. 2005;5:95–101.PubMedCentralPubMedCrossRef

24.

Eckerson HW, Wyte MC, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983;35:1126–38.PubMedCentralPubMed

25.

Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C. 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clim Biochem. 1992;30:391–5.

26.

Nourooz Zadeh J. Ferrous ion oxidation in presence of xylenol orange for detection of lipid hydroperoxides in plasma. Methods Enzymol. 1999;300:58–62.PubMed

27.

Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol. 1994;233:381–5.

28.

Young EJ. Brucella species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6. ed. Philadelphia: Elsevier Churchill Livingstone; 2005;2669–74.

29.

Niemela S, Karttunen T, Korhonen T, et al. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart. 1996;75:573–5.PubMedCentralPubMedCrossRef

30.

Hoffmeister A, Rothenbacher D, Bode G, et al. Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile. Arterioscler Thromb Vasc Biol. 2001;21:427–32.PubMedCrossRef

31.

Altintas E, Ucbilek E, Ulu O, Sezgin O, Uzer C. Helicobacter pylori associated atrophic gastritis and carotid intima-media thickness, is there a link? Int Clin Pract. 2007;61(5):810–4.CrossRef

32.

Van Leeuwen, HJ, Heezius EC, Dallinga GM, van Strijp JA, Verhoef J, van Kessel KP. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med. 2003;31:1359–66.PubMedCrossRef

33.

Aslan M, Nazligul Y, Horoz M, et al. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. Atherosclerosis. 2008;196:270–4.PubMedCrossRef

34.

Mackness B, Mackness MI, Arrol S, et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis. 1998;139:341–9.PubMedCrossRef

35.

Quemeneur T, Martin-Nizard F, Kandoussi A, et al. PON1, a new biomarker of cardiovascular disease, is low in patients with systemic vasculitis. Semin Arthritis Rheum. 2007;37:149–55.PubMedCrossRef

36.

Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991;86:193–9.PubMedCrossRef

37.

Rizzo M, Kotur-Stevuljevic J, Berneis K, Spasojevic- Kalimanovska V, Vekic J. Atherogenic dyslipidemia and oxidative stress: a new look. Transl Res. 2009;153:217–23.PubMedCrossRef

38.

Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci. 2009;84:705–12.PubMedCrossRef

39.

La Du BN, Aviram M, Billecke S, et al. On the physiological role(s) of the paraoxonases. Chem Biol Interact. 1999;119–120:379–88.PubMedCrossRef

40.

Ali EM, Shehata HH, Ali-Labib R, Esmail Zahra LM. Oxidant and antioxidant of arylesterase and paraoxonase as biomarkers in patients with hepatitis C virus. Clin Biochem. 2009;42:1394–1400.PubMedCrossRef

41.

Ates O, Azizi S, Alp HH, Kiziltunc A, Kocer I, Baykal O. Decreased serum paraoxonase 1 activity and increased serum homocysteine and malondialdehyde levels in age-related macular degeneration. Tohoku J Exp Med. 2009;217:17–22.PubMedCrossRef

42.

Kilic SS, Aydin S, Kilic N, Erman F, Aydin S, Celik I. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J Gastroenterol. 2005;11:7351–4.PubMed

43.

Parra S, Alonso-Villaverde C, Coll B, et al. Serum paraoxonase-1 activity and concentration are infl uenced by human immunodefi ciency virus infection. Atherosclerosis. 2007;194:175–81.PubMedCrossRef

44.

Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Biol Med. 1999;26:892–904.CrossRef

45.

Dirican M, Akca R, Sarandol E, Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol. 2004;17:813–8.PubMed

46.

Mackness B, Durington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the caterphilly prospective study. Circulation. 2003;107:2775–9.PubMedCrossRef

47.

Sutherland WHF, Walker RJ, de Jong SA, van Rij AM, Phillips V, Walker HL. Reduced postprandial serum paraoxonase activity after meal rich in used cooking fat. Arterioscler Thromb Vasc Biol. 1999;19:1340–7.PubMedCrossRef

48.

Van der Gaag MS, van Tol A, Scheek LM, et al. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet controlled, randomized intervention study in middle-aged men. Atherosclerosis. 1999;147:405–10.

49.

Chandra M, Chandra N, Agrawal R, Kumar A, Ghatak A, Pandey VC. The free radical system in ischemic heart disease. Int J Cardiol. 1994;43:121–5.PubMedCrossRef

50.

Jarvik GP, Tsai NT, McKinstry LA, et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol. 2004;22:1329–33.CrossRef

51.

Kakafika AI, Xenofontos S, Tsimihodimos V, et al. The PON1 M55 L gene polymorphism is associated with reduced HDL-associated PAF-AH activity. J Lipid Res. 2003;44:1919–26.PubMedCrossRef

52.

Aslan M, Kosecik M, Horoz M, Selek S, Celik H, Erel O. Assessment of paraoxonase and arylesterase activities in patientswith iron deficiency anemia. Atherosclerosis. 2007;191:397–402.PubMedCrossRef

53.

Li HL, Liu DP, Liang CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med. 2003;81(12):766–79.PubMedCrossRef

54.

Sepahvand F, Shafiei M, Ghaffari SM, Rahimi-Moghaddam P, Mahmoudian M. Paraoxonase phenotype distribution in a healthy Iranian population. Basic Clin Pharmacol Toxicol. 2007;101:104–7.PubMedCrossRef

55.

Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol. 2001;21:1451–7.PubMedCrossRef

Titel: Serum paraoxonase activity, total thiols levels, and oxidative status in patients with acute brucellosis
verfasst von: Ramazan Esen
Dr. Mehmet Aslan
Mehmet Emin Kucukoglu
Aytekin Cıkman
Umit Yakan
Mahmut Sunnetcioglu
Sahbettin Selek
Publikationsdatum: 01.06.2015
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 11-12/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-015-0720-z

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11-12/2015

Konsekutive Umstellung auf Tapentadol PR verbessert Analgesie und Lebensqualität bei Patienten mit starken und chronischen Schmerzen unter Tramadol > 300 mg/d

Gregor Gryglewski ist Researcher of the Month Juni 2015

Delayed auditory pathway maturation and prematurity

An outbreak of acute gastroenteritis associated with group A Rotavirus in long-term care facility in Slovenia

Patient’s and physician’s behavior on the management of benign prostatic hyperplasia among the patients at the risk of clinical progression. A multicenter noninterventional trial in Slovakia by “Prostate and Expectations of Treatment: Epidemiology Research” (PETER) study group

The accuracy of urinary ultrasound in the diagnosis of urinary stone disease in patients with acute flank pain: is it influenced by the time of ultrasound performance during the day or week?